Clinical trials for Parotitis

The European Union Clinical Trials Register allows you to search for protocol and results information on:

interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC

clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
Clinical Trials Information System (CTIS).

The EU Clinical Trials Register currently displays 44335 clinical trials with a EudraCT protocol, of which 7366 are clinical trials conducted with subjects less than 18 years old. The register also displays information on 18700 older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).

Examples: Cancer AND drug name. Pneumonia AND sponsor name.
How to search [pdf]

Advanced Search:

Search tools

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Trials with a EudraCT protocol (15)
Paediatric studies in scope of Art45 of the Paediatric Regulation (1)

15 result(s) found for: Parotitis. Displaying page 1 of 1.

EudraCT Number: 2006-003097-97

Sponsor Protocol Number: 00029

Start Date*: 2009-03-09

Sponsor Name:HUS

Full Title: Endoskooppinen kortisoni vaikean juveniilin parotiitin hoidossa

Medical condition: juveniili parotiitti

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	8.1		10034038	Parotitis	LLT

Population Age: Adolescents, Under 18

Gender: Male, Female

Trial protocol: FI (Completed)

Trial results: (No results available)

EudraCT Number: 2011-001608-37

Sponsor Protocol Number: 115555MMRV-063

Start Date*: 2011-12-16

Sponsor Name:GLAXOSMITHKLINE BIOLOGICALS SA

Full Title: Open, randomised, controlled, multicenter Phase IIIb study to evaluate the immune response and safety, after the administration of GlaxoSmithKline Biologicals live attenuated measles mumps rubell...

Medical condition: Vaccination of children from the age of 9 months up to 12 years inclusive against measles, mumps, rubella and varicella diseases

Disease:	Version	SOC Term	Classification Code	Term	Level
	14.1	10021881 - Infections and infestations	10028257	Mumps	PT
	14.1	10021881 - Infections and infestations	10046980	Varicella	PT
	14.1	10021881 - Infections and infestations	10039252	Rubella	PT
	14.1	10021881 - Infections and infestations	10027011	Measles	PT

Population Age: Infants and toddlers, Under 18

Gender: Male, Female

Trial protocol: IT (Completed)

Trial results: View results

EudraCT Number: 2011-004905-26

Sponsor Protocol Number: 115649

Start Date*: 2012-10-10

Sponsor Name:GlaxoSmithKline Biologicals

Full Title: Immunogenicity and safety study of GSK Biologicals’ Priorix® vaccine (209762) at an end of shelf-life potency compared to Merck & Co., Inc.’s MMR vaccine when both are given on a 2-dose schedule to...

Medical condition: Healthy volunteers (Active immunization against measles, mumps and rubella diseases of healthy children in their second year of life).

Disease:	Version	SOC Term	Classification Code	Term	Level
	17.0	10021881 - Infections and infestations	10028257	Mumps	PT
	17.0	10021881 - Infections and infestations	10021881	Infections and infestations	SOC
	17.0	10021881 - Infections and infestations	10039252	Rubella	PT
	17.0	10021881 - Infections and infestations	10027011	Measles	PT

Population Age: Infants and toddlers, Under 18

Gender: Male, Female

Trial protocol: FI (Completed) CZ (Completed) ES (Completed)

Trial results: View results

EudraCT Number: 2011-004891-12

Sponsor Protocol Number: 115648

Start Date*: 2012-11-02

Sponsor Name:GlaxoSmithKline Biologicals

Full Title: A phase IIIA, randomized, observer-blind, controlled, multinational consistency study to evaluate the immunogenicity and safety of GSK Biologicals' MMR vaccine (209762) (Priorix®) compared to Merck...

Medical condition: Healthy volunteers (Active immunization against measles, mumps and rubella diseases of healthy children in their second year of life).

Disease:	Version	SOC Term	Classification Code	Term	Level
	18.0	10021881 - Infections and infestations	10028257	Mumps	PT
	18.0	10021881 - Infections and infestations	10021881	Infections and infestations	SOC
	18.0	10021881 - Infections and infestations	10039252	Rubella	PT
	18.0	10021881 - Infections and infestations	10027011	Measles	PT

Population Age: Infants and toddlers, Under 18

Gender: Male, Female

Trial protocol: EE (Completed) FI (Completed) ES (Completed)

Trial results: View results

EudraCT Number: 2004-002676-41

Sponsor Protocol Number: 100388,103494,104105,104106

Start Date*: 2005-05-23

Sponsor Name:GlaxoSmithKline Biologicals

Full Title: Blinded, randomised, controlled, multicenter study to evaluate the clinical efficacy against varicella disease of GlaxoSmithKline Biologicals’ live attenuated varicella vaccine (Varilrix) given on ...

Medical condition: Healthy children between 12-22 months (including the day before the 23-month birthday) of age at the time of vaccination with no history of measles, mumps, rubella and varicella diseases/vaccination.

Disease:	Version	SOC Term	Classification Code	Term	Level
	14.1	10021881 - Infections and infestations	10028257	Mumps	PT
	14.1	10021881 - Infections and infestations	10046980	Varicella	PT
	14.1	10021881 - Infections and infestations	10039252	Rubella	PT
	14.1	10021881 - Infections and infestations	10027011	Measles	PT

Population Age: Infants and toddlers, Under 18

Gender: Male, Female

Trial protocol: SE (Completed) LT (Completed) SK (Completed) CZ (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2011-004638-32

Sponsor Protocol Number: 115158

Start Date*: 2015-06-11

Sponsor Name:GlaxoSmithKline Biologicals

Full Title: A Phase IIIA, observer-blind, randomized study to evaluate non-inferiority of a second dose of GSK Biologicals’ measles-mumps-rubella vaccine vs. a second dose of Merck & Co., Inc.’s MMR vaccine wh...

Medical condition: Healthy volunteers (Active immunization against measles, mumps and rubella diseases of healthy subjects, 4 to 6 years of age).

Disease:	Version	SOC Term	Classification Code	Term	Level
	18.0	10021881 - Infections and infestations	10028257	Mumps	PT
	18.0	10022891 - Investigations	10059638	Mumps antibody test	PT
	18.0	10021881 - Infections and infestations	10027015	Measles like illness	LLT
	18.0	10021881 - Infections and infestations	10039270	Rubella viral infections	HLT
	18.0	10021881 - Infections and infestations	10027011	Measles	PT
	18.0	100000004858	10027022	Measles-like rash	LLT
	18.0	10022891 - Investigations	10039261	Rubella immunity (confirmed)	LLT
	18.0	10021881 - Infections and infestations	10028262	Mumps like illness	LLT
	18.0	10021881 - Infections and infestations	10039252	Rubella	PT
	18.0	10022891 - Investigations	10060066	Measles antibody	PT
	18.0	10022891 - Investigations	10039255	Rubella antibodies not present	LLT
	18.0	10021881 - Infections and infestations	10028268	Mumps viral infections	HLT
	18.0	10022891 - Investigations	10039259	Rubella antibody test	PT

Population Age: Children, Under 18

Gender: Male, Female

Trial protocol: Outside EU/EEA

Trial results: View results

EudraCT Number: 2005-005825-75

Sponsor Protocol Number: 105909 MeMuRu-OKA 047

Start Date*: 2006-03-20

Sponsor Name:GLAXO SMITHKLINE

Full Title: A phase II, open, randomised, comparative study to evaluate the immunogenicity and safety of GlaxoSmithKline s GSK Biologicals measles-mumps-rubella-varicella candidate vaccine MeMuRu-OKA and ...

Medical condition: Active immunisation against mumps, measles, rubella and varicella

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	6.1		10046980		PT

Population Age: Infants and toddlers, Children, Under 18

Gender: Male, Female

Trial protocol: IT (Completed)

Trial results: View results

EudraCT Number: 2004-002669-19

Sponsor Protocol Number: X04-VAR-402

Start Date*: 2004-12-23

Sponsor Name:AVENTIS PASTEUR MSD S.P.A.

Full Title: A double-blind, randomised, controlled, multi-centre safety study of a refrigerator-stable formulation of VARIVAX® in healthy 12 to 15 month-old infants.

Medical condition: Active immunisation against varicella

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	6.1		10046980		PT

Population Age: Infants and toddlers, Under 18

Gender: Male, Female

Trial protocol: IT (Completed)

Trial results: View results

EudraCT Number: 2011-003672-36

Sponsor Protocol Number: 115231,MMR159

Start Date*: 2014-10-09

Sponsor Name:GlaxoSmithKline Biologicals S.A.

Medical condition: Healthy volunteers (Active immunization against measles, mumps and rubella diseases of healthy subjects, 7 years of age and older).

Disease:	Version	SOC Term	Classification Code	Term	Level
	17.1	100000004865	10069547	Mumps immunization	LLT
	17.1	100000004862	10039276	Rubella with unspecified complications	LLT
	17.1	100000004865	10069545	Measles immunization	LLT
	17.1	100000004862	10039274	Rubella with other specified complication	LLT
	17.1	100000004865	10069564	Rubella immunization	LLT
	17.1	100000004862	10028274	Mumps with other specified complication	LLT
	17.1	100000004862	10027021	Measles without mention of complication	LLT
	17.1	100000004862	10027020	Measles with unspecified complication	LLT
	17.1	100000004858	10027022	Measles-like rash	LLT

Population Age: Children, Under 18, Adults

Gender: Male, Female

Trial protocol: SK (Completed) EE (Completed)

Trial results: View results

EudraCT Number: 2011-006161-18

Sponsor Protocol Number: 115650

Start Date*: 2014-09-25

Sponsor Name:GlaxoSmithKline Biologicals

Full Title: A phase IIIA, randomized, observer-blind, controlled, multinational study to evaluate the safety and immunogenicity of GSK Biologicals' MMR vaccine (209762) (Priorix®) compared to Merck & Co., Inc....

Medical condition: Healthy volunteers (Active immunization against measles, mumps and rubella diseases in healthy children, 12 to 15 months of age)

Disease:	Version	SOC Term	Classification Code	Term	Level
	18.0	100000004865	10069547	Mumps immunization	LLT
	18.0	100000004862	10039276	Rubella with unspecified complications	LLT
	18.0	100000004862	10039274	Rubella with other specified complication	LLT
	18.0	100000004865	10069545	Measles immunization	LLT
	18.0	100000004865	10069564	Rubella immunization	LLT
	18.0	100000004862	10028276	Mumps with unspecified complication	LLT
	18.0	100000004862	10027015	Measles like illness	LLT
	18.0	100000004862	10028275	Mumps with other specified complications	LLT
	18.0	100000004862	10027021	Measles without mention of complication	LLT
	18.0	100000004862	10027020	Measles with unspecified complication	LLT
	18.0	100000004858	10027022	Measles-like rash	LLT

Population Age: Infants and toddlers, Under 18

Gender: Male, Female

Trial protocol: EE (Completed) FI (Completed)

Trial results: View results

EudraCT Number: 2011-004485-15	Sponsor Protocol Number: 110876	Start Date*: 2015-06-25
Sponsor Name:GlaxoSmithKline Biologicals
Full Title: A Phase IIIb, open, randomized study to evaluate non-inferiority of GSK Biologicals’ measles-mumps-rubella-varicella vaccine versus co-administration of GSK Biologicals’ Priorix™ and Varilrix™ in h...
Medical condition: Measles, mumps, rubella and varicella diseases
Disease:
Population Age: Infants and toddlers, Under 18		Gender: Male, Female
Trial protocol: Outside EU/EEA
Trial results: View results

EudraCT Number: 2011-005881-38	Sponsor Protocol Number: 108760	Start Date*: 2015-06-25
Sponsor Name:GlaxoSmithKline Biologicals
Full Title: A phase II, randomized, double-blind study of Priorix-Tetra (combined measles-mumps-rubella-varicella vaccine), one lot using new measles and rubella working seeds and one lot using old working see...
Medical condition: Measles, mumps, rubella and varicella diseases
Disease:
Population Age: Infants and toddlers, Under 18		Gender: Male, Female
Trial protocol: Outside EU/EEA
Trial results: View results

EudraCT Number: 2005-006065-14	Sponsor Protocol Number: 105908	Start Date*: 2006-04-04
Sponsor Name:GlaxoSmithKline Biologicals
Full Title: A phase II, open, randomised, comparative study to evaluate the immunogenicity and safety of GlaxoSmithKline's (GSK) Biologicals' measles-mumps-rubella-varicella candidate vaccine (MeMuRu-OKA) and ...
Medical condition: Healthy male and female children between 15 months and 6 years of age who previously received an MMR vaccine will receive one dose of MMR + V or MMRV. A second dose of varicella vaccine will be giv...
Disease:
Population Age: Infants and toddlers, Children, Under 18		Gender: Male, Female
Trial protocol: DE (Completed) IT (Completed)
Trial results: View results

EudraCT Number: 2013-001332-22

Sponsor Protocol Number: RG_12-201

Start Date*: 2013-06-20

Sponsor Name:University of Birmingham

Full Title: PEPtalk 2: Pilot of a randomised controlled trial to compare VZIG and aciclovir as post-exposure prophylaxis against chickenpox in children with cancer

Medical condition: Exposure to Varicella by children who have cancer.

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	17.1	10021881 - Infections and infestations	10046980	Varicella	PT

Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: GB (Completed)

Trial results: View results

EudraCT Number: 2013-003535-30

Sponsor Protocol Number: 200147

Start Date*: 2015-10-13

Sponsor Name:GlaxoSmithKline Biologicals

Full Title: A Phase III, double blind, randomized, comparative study of the safety and immunogenicity of GSK Biologicals’ Varilrix HSA-free varicella vaccine and Varilrix™ given as a 2 dose course in the secon...

Medical condition: Vaccinating Healthy volunteers (Active immunization against varicella virus disease of healthy children in their second year of life).

Disease:	Version	SOC Term	Classification Code	Term	Level
	19.0	10042613 - Surgical and medical procedures	10069613	Varicella immunisation	PT
	19.0	10042613 - Surgical and medical procedures	10069628	Varicella immunization	LLT
	19.0	100000004848	10063315	Varicella zoster virus DNA test positive	LLT
	19.0	10021881 - Infections and infestations	10046983	Varicella zoster	LLT
	19.0	10021881 - Infections and infestations	10046980	Varicella	PT
	19.0	100000004858	10050331	Varicella-like rash	LLT
	19.0	100000004848	10063144	Varicella zoster virus serology positive	LLT

Population Age: Infants and toddlers, Under 18

Gender: Male, Female

Trial protocol: DE (Completed) GB (Completed) EE (Completed)

Trial results: View results

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

For support, Contact us.

The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

European Medicines Agency © 1995-Tue May 13 12:17:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA